Herein, we revealed that ovarian cancer cells with PIK3CA/PTEN mutations are sensitive to PI3K/Akt inhibitors; this finding is mainly consistent with those obtained in breast or prostate cancer cells (Davies et al., 2012; Hancox et al., 2015; Hudson et al., 2016). Here, PIK3CB is linked to prostate carcinoma.